Author

D. Dow

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

E. Goncalves· 2 shared F. Iorio· 2 shared G. Picco· 2 shared J. Saez-Rodriguez· 2 shared K. Yusa· 2 shared A. Butler· 1 shared A. Matchan· 1 shared B. Fu· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Goncalves

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening

M. Garnett, G. Picco, E. Chen, L. Garcia Alonso, F. Behan, E. Goncalves, G. Bignell, A. Matchan, B. Fu, R. Banerjee, E. Anderson, A. Butler, C. Benes, U. McDermott, D. Dow, , J. Saez-Rodriguez

The paper functionally links gene fusions to cancer cell fitness using drug sensitivity and CRISPR-Cas9 data, identifying rare functional fusions and novel therapeutic targets.

bioRxiv · Feb 24, 2019Cancer Biology

Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening

F. M. Behan, F. Iorio, E. Goncalves, G. Picco, C. M. Beaver, R. Santos, Y. Rao, R. Ansari, S. Harper, D. A. Jackson, R. McRae, R. Pooley, P. Wilkinson, D. Dow, C. Buser-Doepner, , G. J. Mathew

This study uses CRISPR-Cas9 screens in cancer cell lines to identify and prioritize new oncology therapeutic targets based on gene fitness, biomarkers, and tractability.

bioRxiv · Dec 20, 2018Cancer Biology